Hosted on MSN21d
After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.
Eli Lilly now expects $13.5 billion in fourth-quarter ... Follow Allison Gatlin on X/Twitter at @IBD_AGatlin.
What Analysts Think of Eli Lilly Stock Ahead of Earnings
Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels. Eli Lilly ...
Hosted on MSN22d
Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales Slow
Eli Lilly stock also has a Composite Rating of 82, a measure of fundamental and technical metrics. Follow Reinhardt Krause on Twitter @reinhardtk_tech for updates on artificial intelligence ...
Business Insider26d
Lilly in advanced talks to buy cancer biotech Scorpion for up to $2.5B, FT says
Eli Lilly (LLY) is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5B, people close to the talks told Financial Times’ Oliver Barnes, Maria Heeter ...